eMedicine Specialties > Hematology > Coagulation, Hemostasis, and Disorders

Factor VII: Follow-up

Author: Jeyanthi Ramanarayanan, MD, Attending Physician, Department of Medicine, Division of Hematology and Medical Oncology, Stratton Veterans Affairs Medical Center
Coauthor(s): Ganapathy S Krishnan, MBBS, Fellow, Department of Hematology and Oncology, Michigan State University; Francisco J Hernandez-Ilizaliturri, MD, Assistant Professor, Departments of Medicine and Immunology, Roswell Park Cancer Institute, State University of New York at Buffalo
Contributor Information and Disclosures

Updated: Feb 14, 2008

Follow-up

Further Outpatient Care

Perform annual history and physical examinations and test for hepatitis virus and HIV. Order MRI or CT scans for follow-up of joint deformities. Regular screening tests include cholesterol, prostate-specific antigen levels, colonoscopy, and mammography. In addition, vaccination for hepatitis A and B viruses, dental care, orthopedic follow-up, and patient education are recommended.

Complications

Infectious complications from transfusion of plasma or factor concentrates include HIV infection and hepatitis. Transmission of other infectious disease is always a theoretical possibility (eg, variant Creutzfeldt-Jakob disease). Recurrent hemarthrosis leads to joint deformities and disability. Occupational and social rehabilitation is necessary.

Prognosis

Recombinant agent therapy and early intervention of joint disease may result in improved outcomes, as in persons with hemophilia A.

Patient Education

  • Patients and family members should be educated about the disease and its transmission. Genetic counseling is recommended. Advise patients to seek medical attention early during the development of symptoms, to consult with specialists, and to comply with follow-up requirements.
  • For excellent patient education resources, visit eMedicine's Blood and Lymphatic System Center. Also, see eMedicine's patient education article Hemophilia.

Miscellaneous

Medicolegal Pitfalls

  • Failure to recognize contraindications to specific agents required for treatment
  • Failure to educate patients regarding the disorder, including recommendations for genetic testing, information regarding early bleeding symptoms, and precautions about infectious risks of certain blood products
  • Failure to recognize that factor VII levels do not always correlate with the amount and severity of bleeding
  • Misdiagnosis of the type of factor disorder
 


More on Factor VII

Overview: Factor VII
Differential Diagnoses & Workup: Factor VII
Treatment & Medication: Factor VII
Follow-up: Factor VII
Multimedia: Factor VII
References
[ CLOSE WINDOW ]

References

  1. Alexander B, R Goldstein and G Landwehr, CooK CD. Congenital SPCA deficiency: a hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J Clin Invest. Jun 1951;30(6):596-608. [Medline].

  2. Roberts HR, Monroe DM, Hoffman M. Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. William's Hematology. 2001. 6th ed. New York, NY: McGraw-Hill; 2001:1409-34.

  3. Lane A, Cruickshank JK, Mitchell J, et al. Genetic and environmental determinants of factor VII coagulant activity in ethnic groups at differing risk of coronary heart disease. Atherosclerosis. May 1992;94(1):43-50. [Medline].

  4. Pinotti M, Toso R, Girelli D, et al. Modulation of factor VII levels by intron 7 polymorphisms: population and in vitro studies. Blood. Jun 1 2000;95(11):3423-8. [Medline].

  5. Laurian Y. Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?. Pathophysiol Haemost Thromb. 2002;32 Suppl 1:37-40. [Medline].

  6. Herrmann FH, Wulff K, Auberger K, et al. Molecular biology and clinical manifestation of hereditary factor VIIdeficiency. Semin Thromb Hemost. 2000;26(4):393-400. [Medline].

  7. Bernardi F, Patracchini P, Gemmati D, et al. Molecular analysis of factor VII deficiency in Italy: a frequent mutation(FVII Lazio) in a repeated intronic region. Hum Genet. Nov 1993;92(5):446-50. [Medline].

  8. Cutler JA, Patel R, Mitchell MJ, Savidge GF. The significance of published polymorphisms in 14 cases of mild factor VII deficiency. Blood Coagul Fibrinolysis. Mar 2005;16(2):91-5. [Medline].

  9. Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors, and long-term incidence ofischaemic heart disease in the Northwick Park Heart Study. Lancet. Oct 30 1993;342(8879):1076-9. [Medline].

  10. Moor E, Silveira A, van't Hooft F, et al. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age: role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol. 15(5):655-664.

  11. Rodgers GM, Greenberg CS. Inherited coagulation disorders. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe's Clinical Hematology. Vol 2. 10th ed. Baltimore, Md: Williams & Wilkins; 1999:1682-732.

  12. Heywood DM, Carter AM, Catto AJ, et al. Polymorphisms of the factor VII gene and circulating FVII:C levels in relation to acute cerebrovascular disease and poststroke mortality. Stroke. Apr 1997;28(4):816-21. [Medline].

  13. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. Jan 18 2003;361(9353):201-5. [Medline].

  14. Seligsohn U, White GC. Inherited deficiencies of coagulation factors II, V, VII, XI and XIII and the combined deficiencies of factors V and VII and of the vitamin K-dependent factors. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. William's Hematology. 6th ed. New York, NY: McGraw-Hill; 2001:1617-38.

  15. Giansily-Blaizot M, Schved JF. Potential predictors of bleeding risk in inherited factorVII deficiency. Clinical, biological and molecular criteria. Thrombosis and Hemostasis. 2005;94:899-900.

  16. Mariani G, Herrmann FH, Dolce A, et al. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost. Mar 2005;93(3):481-7. [Medline].

  17. Mariani G, Lapecorella M, Dolce A. Steps towards an effective treatment strategy in congenital factor VII deficiency. Seminars in Hematology. 2006;43:42-47.

  18. Mannucci PM and Levi M. Prevention and treatment of major blood loss. NEJM. MAY/2007;356:2301-2311. [Medline].

  19. Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults. Stroke 2001-23. JUNE/2007;38:2001-2023. [Medline].

  20. Ludlam CA. The evidence behind inhibitor treatment with recombinant factor VIIa. Pathophysiol Haemost Thromb. 2002;32 Suppl 1:13-8. [Medline].

  21. Lisman T, Moschatsis S, Adelmeijer J, et al. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood. Mar 1 2003;101(5):1864-70. [Medline].

  22. Ludlam CA, Smith MP, Morfini M, et al. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol. Mar 2003;120(5):808-13. [Medline].

  23. Butenas S, Brummel KE, Branda RF, et al. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood. Feb 1 2002;99(3):923-30. [Medline].

  24. Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis. Mar 1998;9 Suppl 1:S15-20. [Medline].

  25. [Best Evidence] Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. Feb 24 2005;352(8):777-85. [Medline].

  26. Barletta JF, Ahrens CL, Tyburski JG, Wilson RF. A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients. J Trauma. Mar 2005;58(3):646-51. [Medline].

  27. Bidot CJ, Jy W, Horstman LL, et al. Factor VII/VIIa: a new antigen in the anti-phospholipid antibody syndrome. Br J Haematol. Feb 2003;120(4):618-26. [Medline].

  28. Butenas S, van''t Veer C, Mann KG. "Normal" thrombin generation. Blood. Oct 1 1999;94(7):2169-78. [Medline].

  29. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinanthuman factor VIIa concentrate. Ann Intern Med. Dec 3 2002;137(11):884-8. [Medline].

  30. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost. Jun 2001;85(6):958-65. [Medline].

  31. Iacoviello L, Di Castelnuovo A, De Knijff P, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med. Jan 8 1998;338(2):79-85. [Medline].

  32. Kavakli K, Makris M, Zulfikar B. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thrombosis and hemostasis. 2006;95:600-605.

  33. Mariani G, Herrmann FH, Bernardi F, et al. Clinical manifestations, management, and molecular genetics in congenitalfactor VII deficiency: the International Registry on Congenital Factor VII Deficiency (IRF7). Blood. Jul 1 2000;96(1):374. [Medline].

  34. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. Dec 15 2004;104(13):3858-64. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

FVII, F7 gene, proconvertin, stable factor, serum prothrombin conversion accelerator, SPCA, autoprothrombin I, recombinant factor VIIa, rFVIIa, NovoSeven, coagulation, procoagulants, coagulation cascade, anticoagulant factors, Dubin-Johnson syndrome, Rotor syndrome, prothrombin conversion accelerator deficiency, coagulation disorder, blood disorder blood disease, hemophilia A, hemophilia, hemophilia B

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Jeyanthi Ramanarayanan, MD, Attending Physician, Department of Medicine, Division of Hematology and Medical Oncology, Stratton Veterans Affairs Medical Center
Jeyanthi Ramanarayanan, MD is a member of the following medical societies: American Association of Physicians of Indian Origin, American Society of Clinical Oncology, and American Society of Hematology
Disclosure: Nothing to disclose.

Coauthor(s)

Ganapathy S Krishnan, MBBS, Fellow, Department of Hematology and Oncology, Michigan State University
Disclosure: Nothing to disclose.

Francisco J Hernandez-Ilizaliturri, MD, Assistant Professor, Departments of Medicine and Immunology, Roswell Park Cancer Institute, State University of New York at Buffalo
Francisco J Hernandez-Ilizaliturri, MD is a member of the following medical societies: American Association for Cancer Research, American Society of Clinical Oncology, and American Society of Hematology
Disclosure: Nothing to disclose.

Medical Editor

Paul Schick, MD, Emeritus Professor, Department of Internal Medicine, Thomas Jefferson University Medical College; Research Professor, Department of Internal Medicine, Drexel University College of Medicine
Paul Schick, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Society of Hematology, International Society on Thrombosis and Haemostasis, and New York Academy of Sciences
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Ronald A Sacher, MB, BCh, MD, FRCPC, Director of the Hoxworth Blood Center, Professor, Departments of Internal Medicine and Pathology, University of Cincinnati Medical Center
Ronald A Sacher, MB, BCh, MD, FRCPC is a member of the following medical societies: American Society of Hematology
Disclosure: Glaxo Smith Kline Honoraria Speaking and teaching; Talecris Honoraria Board membership

CME Editor

Rebecca J Schmidt, DO, FACP, FASN, Professor of Medicine, Section Chief, Department of Medicine, Section of Nephrology, West Virginia University School of Medicine
Rebecca J Schmidt, DO, FACP, FASN is a member of the following medical societies: American College of Osteopathic Internists, American College of Physicians, American Medical Association, American Society of Nephrology, International Society of Nephrology, National Kidney Foundation, Renal Physicians Association, and West Virginia State Medical Association
Disclosure: Abbott Grant/research funds Speaking and teaching; Genzyme Honoraria Consulting; Roche Honoraria Consulting

Chief Editor

Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University
Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Clinical Oncology, American Society of Hematology, and New York Academy of Sciences
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.